There were 1,807 press releases posted in the last 24 hours and 443,051 in the last 365 days.

Delisting of Securities of Schmitt Industries, Inc.; Viveve Medical, Inc.; and American Virtual Cloud Technologies, Inc. from The Nasdaq Stock Market

NEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of Schmitt Industries, Inc. Schmitt Industries, Inc.’s common stock was suspended on January 17, 2023, and has not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the common stock of Viveve Medical, Inc. Viveve Medical, Inc.’s common stock was suspended on January 19, 2023, and has not traded on Nasdaq since that time.

Nasdaq also announced today that it will delist the Common Stock and Warrant expiring 4/7/2025 of American Virtual Cloud Technologies, Inc. American Virtual Cloud Technologies, Inc.’s securities were suspended on January 20, 2023, and have not traded on Nasdaq since that time.

Nasdaq will file a Form 25 with the Securities and Exchange Commission to complete the delistings. The delistings become effective ten days after the Form 25 is filed. For news and additional information about the companies, including the basis for the delisting and whether the companies’ securities are trading on another venue, please review the companies’ public filings or contact the company directly.

For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com. Nasdaq’s rules governing the delisting of securities can be found in the Nasdaq Rule 5800 Series, available on the Nasdaq Web site: https://listingcenter.nasdaq.com/rulebook/nasdaq/rules/nasdaq-5800-series.

-NDAQO-


Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.